Insmed Incorporated (NASDAQ:INSM) CEO William Lewis Sells 79,350 Shares

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 79,350 shares of the stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $80.90, for a total transaction of $6,419,415.00. Following the transaction, the chief executive officer now directly owns 453,894 shares in the company, valued at $36,720,024.60. The trade was a 14.88 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

William Lewis also recently made the following trade(s):

• On Monday, February 3rd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $77.94, for a total value of $1,461,375.00.
• On Wednesday, January 15th, William Lewis sold 31,805 shares of Insmed stock. The stock was sold at an average price of $70.18, for a total value of $2,232,074.90.
• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The shares were sold at an average price of $63.36, for a total value of $188,686.08.
• On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The stock was sold at an average price of $66.02, for a total transaction of $542,552.36.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $69.84, for a total transaction of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.91, for a total transaction of $1,310,812.50.

Insmed Stock Down 1.0 %

Shares of INSM stock opened at $79.95 on Monday. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $82.04. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The business’s fifty day moving average is $72.88 and its 200-day moving average is $73.09. The stock has a market cap of $14.30 billion, a PE ratio of -14.41 and a beta of 1.11.

Analysts Set New Price Targets

A number of brokerages have commented on INSM. Truist Financial restated a “buy” rating and issued a $105.00 target price (up from $100.00) on shares of Insmed in a research note on Friday, November 1st. Guggenheim boosted their price objective on Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a research report on Friday. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 target price on shares of Insmed in a research report on Friday, November 1st. Morgan Stanley boosted their price target on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday. Finally, JPMorgan Chase & Co. increased their price objective on shares of Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a report on Friday. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to data from MarketBeat, Insmed currently has an average rating of “Moderate Buy” and an average target price of $85.00.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of INSM. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Insmed by 18.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 43,476 shares of the biopharmaceutical company’s stock valued at $3,002,000 after purchasing an additional 6,755 shares in the last quarter. Edgestream Partners L.P. boosted its holdings in Insmed by 1,242.1% during the fourth quarter. Edgestream Partners L.P. now owns 43,619 shares of the biopharmaceutical company’s stock worth $3,011,000 after buying an additional 40,369 shares in the last quarter. Arizona State Retirement System grew its position in Insmed by 6.1% in the fourth quarter. Arizona State Retirement System now owns 47,342 shares of the biopharmaceutical company’s stock worth $3,268,000 after buying an additional 2,722 shares during the last quarter. Aigen Investment Management LP increased its holdings in shares of Insmed by 193.3% in the fourth quarter. Aigen Investment Management LP now owns 11,936 shares of the biopharmaceutical company’s stock valued at $824,000 after buying an additional 7,867 shares in the last quarter. Finally, Proficio Capital Partners LLC bought a new position in shares of Insmed in the fourth quarter valued at $1,864,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.